 |
MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company's Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC) therapy, TLX591 (177Lu...
Hashtag.net.au
Look at the Range of Dental Care Available Choosing a dental practice is easier when patients can access different types of care in one place. A dental clinic Melbourne patients visit may provide gen...
Hashtag.net.au
In clinical settings, surgical supply partners aren’t just vendors. They sit quietly behind the scenes of operating lists, specialist consultations, treatment rooms and recovery workflows. When they...
Hashtag.net.au
The early developmental years of a child's life represent a critical window for neurological growth, behavioural shaping, and language acquisition. During this formative phase, the ability to interpre...